Inmune Bio Plans US, UK, and European Approvals for Skin Disorder Treatment

INmune Bio, a clinical-stage biotech firm, is developing treatments for various diseases by targeting the innate immune system. It has two therapeutic platforms: DN-TNF and NK or INKmune. DN-TNF products, such as pegipanermin, are in clinical trials for cancer, Alzheimer's disease, and depression. INKmune aims to eliminate minimal residual disease in cancer patients. The company is seeking approval in the US, UK, and Europe for its treatments.

INmune Bio, a clinical-stage biotech firm, is making waves in the industry with its unique approach to developing treatments for various diseases by targeting the innate immune system. With two therapeutic platforms, DN-TNF and NK or INKmune, INmune Bio is poised to make a significant impact on cancer, Alzheimer's disease, and depression treatments [1].

INmune Bio's clinical development approach is centered around matching the drug mechanism to patient biology and using relevant outcome metrics [1]. The mechanism of action of the drug should align with the underlying biology of the patient population being treated. Moreover, clinical trial outcomes should directly measure the expected benefits of the drug on patients.

One of INmune Bio's most promising candidates is XPro1595, an investigational dominant-negative protein that neutralizes soluble TNF. This drug has shown promising results in a Phase 1b study for Alzheimer's disease (AD) [2]. Interim data revealed that XPro1595 decreases biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid (CSF) and MRI [2]. The data suggest that decreasing neuroinflammation results in significant improvements in biomarkers of neurodegeneration and synaptic function [2].

The ongoing Phase 1b open-label dose escalation trial aims to demonstrate that XPro1595, when given as a subcutaneous injection once weekly, will decrease neuroinflammation in patients with mild to moderate AD [2]. Preliminary results show that cytokine/chemokine CSF levels after 12 weeks of therapy were decreased, with multiple statistically significant reductions [2]. Additionally, there was a significant correlation between neuroinflammation, as measured by CSF, and MRI [2].

INmune Bio is seeking approval in the US, UK, and Europe for its treatments, including XPro1595 [1]. The company's focus on patient benefit and innovative approach to clinical development make it an exciting player to watch in the world of biotech.

References:

[1] INmune Bio. Our Approach to Clinical Development. https://inmunebio.com/

[2] INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer's Disease in Phase 1b Trial. https://www.inmunebio.com/index.php/newsroom/2021-news/inmune-bio-inc-announces-xpro1595-found-to-decrease-neuroinflammation-and-neurodegeneration-biomarkers-in-patients-with-alzheimers-disease-in-phase-1b-trial